FindTrial
Sign In

ladiratuzumab vedotin

DRUG4 trials

Sponsors

Seagen Inc.

Conditions

Esophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHER2 Mutations Breast NeoplasmsHER2 Positive Breast NeoplasmsHead and Neck Squamous Cell CarcinomaHormone Receptor Positive Breast NeoplasmsMelanoma

Phase 1

A Safety Study of SGN-LIV1A in Breast Cancer Patients
CompletedNCT01969643
Seagen Inc.HER2 Mutations Breast Neoplasms, HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms +1
Start: 2013-10-22End: 2023-02-04Updated: 2023-03-07
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
CompletedNCT03310957
Seagen Inc.Triple Negative Breast Neoplasms
Start: 2018-02-27End: 2024-09-30Updated: 2025-12-12

Phase 2

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
TerminatedNCT04032704
Seagen Inc.Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma +6
Start: 2019-10-09End: 2023-11-28Updated: 2025-03-10

Unknown Phase

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT06362590
Seagen Inc.
Updated: 2026-09-08

Related Papers

Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Cancer Research2023-03-014 citations
Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress).
Journal of Clinical Oncology2022-06-0112 citations
Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).
Journal of Clinical Oncology2021-02-201 citations
Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
Cancer Research2021-02-151 citations
Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).
Journal of Clinical Oncology2021-01-204 citations
323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
Regular and Young Investigator Award Abstracts2020-11-014 citations
SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.
Journal of Clinical Oncology2020-05-207 citations
Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Cancer Research2020-02-1539 citations
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies.
Journal of Clinical Oncology2020-02-012 citations
SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Journal of Clinical Oncology2019-05-2031 citations
Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
Annals of Oncology2018-10-012 citations
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
Cancer Research2018-02-1567 citations
Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
Cancer Research2017-02-153 citations
Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
Cancer Research2016-02-154 citations
Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer
Cancer Research2015-05-01
SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1–positive breast cancer.
Journal of Clinical Oncology2014-05-205 citations